Multixenobiotic resistance as a cellular defense mechanism in aquatic organisms

被引:328
作者
Bard, SM [1 ]
机构
[1] Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA
关键词
multidrug resistance; multixenobiotic resistance; P-glycoprotein; marine; aquatic; fish;
D O I
10.1016/S0166-445X(00)00088-6
中图分类号
Q17 [水生生物学];
学科分类号
071004 ;
摘要
Multixenobiotic resistance in aquatic organisms exposed to natural toxins or anthropogenic contaminants is a phenomenon analogous to multidrug resistance in mammalian tumor cell lines tolerant of anti-cancer drugs. Multidrug resistance is commonly due to the elevated expression of transmembrane P-glycoproteins (P-gp) which actively transport a wide variety of structurally and functionally diverse compounds. The purpose of this review is to place aquatic ecotoxicological data in context of the larger multidrug resistance field of study. Information on P-glycoproteins structure, mechanism of transport, and substrate specificity gained through traditional mammalian and cell culture models is examined in conjunction with recent work on aquatic species exposed to xenobiotics both in the field and in the laboratory. The physiological function of P-glycoproteins is explored through studies of gene knockout models and expression patterns in normal tissues and tumors. The effect of xenobiotic exposures on P-gp activity and protein titer is examined in wild and captive populations of aquatic invertebrates and vertebrates. Substrate overlap and evidence of co-expression of phase I detoxification enzymes (e.g. cytochromes P450) and P-gp are presented. The role of P-gp chemosensitizers as environmental pollutants and the ecotoxicological consequences of P-gp inhibition are highlighted. The overwhelming evidence suggests that P-glycoproteins provide aquatic organisms with resistance to a wide range of natural and anthropogenic toxins. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:357 / 389
页数:33
相关论文
共 237 条
[1]   THE MULTIDRUG RESISTANCE (MDR1) GENE-PRODUCT FUNCTIONS AS AN ATP CHANNEL [J].
ABRAHAM, EH ;
PRAT, AG ;
GERWECK, L ;
SENEVERATNE, T ;
ARCECI, RJ ;
KRAMER, R ;
GUIDOTTI, G ;
CANTIELLO, HF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (01) :312-316
[2]   Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay [J].
Aherne, GW ;
Hardcastle, A ;
Valenti, M ;
Bryant, A ;
Rogers, P ;
Pettit, GR ;
Srirangam, JK ;
Kelland, LR .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 (03) :225-232
[3]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[4]  
Bain LJ, 1997, ENVIRON HEALTH PERSP, V105, P812, DOI 10.2307/3433698
[5]  
Bain LJ, 1996, TOXICOL APPL PHARM, V141, P288, DOI 10.1016/S0041-008X(96)80035-4
[6]  
BARD S, 1997, 18 ANN M SOC ENV TOX
[7]  
BARD SM, 1998, TOXICOL SCI, V42, P16
[8]  
BARD SM, 1909, PRIMO, V10, P90
[9]   EXPRESSION OF A DRUG-RESISTANCE GENE IN HUMAN NEURO-BLASTOMA CELL-LINES - MODULATION BY RETINOIC ACID-INDUCED DIFFERENTIATION [J].
BATES, SE ;
MICKLEY, LA ;
CHEN, YN ;
RICHERT, N ;
RUDICK, J ;
BIEDLER, JL ;
FOJO, AT .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (10) :4337-4344
[10]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258